Sun Pharmaceutical Industries witnessed a rise in share price on Tuesday after the company'one of the wholly owned subsidiaries has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Zetia, (ezetimibe) Tablets 10mg.

These generic ezetimibe tablets are therapeutic equivalents of Merck’s Zetia tablets. As per IMS, ezetimibe tablets had annual sales of approximately $2.7 billion in the US for the 12 months ended April 2017.

Shares of Sun Pharmaceutical Industries are trading at Rs 542.25, up Rs 9.1, or 1.71% at the Bombay Stock Exchange (BSE) on Tuesday at 10:15 a.m.

The scrip has touched an intra-day high of Rs 551.40 and low of Rs 540.20. The total volume of shares traded at the BSE is 292,024.

Total volume of shares traded on the bourses today was lower by 48.64% to 4,330,973 compared with 22-day average volume of 8,432,694.